Quentin Adams1, Karolyn M Hopfensperger2, Yusung Kim1, Xiaodong Wu1,3, Ryan T Flynn1. 1. Department of Radiation Oncology, University of Iowa, 200 Hawkins Drive, Iowa City, Iowa, 52242, USA. 2. Department of Biomedical Engineering, University of Iowa, 1402 Seamans Center for the Engineering Arts and Sciences, Iowa City, Iowa, 52242, USA. 3. Department of Electrical and Computer Engineering, University of Iowa, 4016 Seamans Center for the Engineering Arts and Sciences, Iowa City, IA, 52242, USA.
Abstract
PURPOSE: To present a system for the treatment of prostate cancer in a single-fraction regimen using 169 Yb-based rotating shield brachytherapy (RSBT) with a single-catheter robotic delivery system. The proposed system is innovative because it can deliver RSBT through multiple implanted needles independently, in serial, using flexible catheters, with no inter-needle shielding effects and without the need to rotate multiple shielded catheters inside the needles simultaneously, resulting in a simple, mechanically robust, delivery approach. RSBT was compared to conventional 192 Ir-based high-dose-rate brachytherapy (HDR-BT) in a treatment planning study with dose escalation and urethral sparing goals, representing single-fraction brachytherapy monotherapy and brachytherapy as a boost to external beam radiotherapy, respectively. A prototype mechanical delivery system was constructed and quantitatively evaluated as a proof of concept. METHODS: Treatment plans for twenty-six patients with single fraction prescriptions of 20.5 and 15 Gy, were created for dose escalation and urethral sparing, respectively. The RSBT and HDR-BT delivery systems were modeled with one partially shielded 999 GBq (27 Ci) 169 Yb source and one 370 GBq (10 Ci) 192 Ir source, respectively. A prototype angular drive system for helical source delivery was constructed. Mechanical accuracy measurements of source translational position and angular orientation in a simulated treatment delivery setup were obtained using the prototype system. RESULTS: For dose escalation, with equivalent urethra D10% , PTV D90% for RSBT vs HDR-BT increased from 22.6 ± 0.0 Gy (average ± standard deviation) to 29.3 ± 0.9 Gy, or 29.9 % ± 3.0%, with treatment times of 51.4 ± 6.1 min for RSBT and 15.8 ± 2.3 min for 10 Ci 192 Ir-based HDR-BT. For urethra sparing, with equivalent PTV D90 % , urethra D10% for RSBT vs HDR-BT decreased for RSBT vs HDR-BT from 15.6 ± 0.4 Gy to 12.0 ± 0.4 Gy, or 23.1% ± 3.5%, with treatment times of 30.0 ± 3.7 min for RSBT and 12.3 ± 1.8 min for HDR-BT. Differences between measured vs predicted rotating catheter positions (corresponding to source position) were within 0.18 mm ± 0.12 mm longitudinally and 0.07° ± 0.78°. CONCLUSION: 169 Yb-based RSBT can increase PTV D90% or decrease urethral D10% relative to HDR-BT with treatment times of less than 1 h using a single-source robotic delivery system with treatment delivered in a single fraction. The prototype helical delivery system was able to demonstrate adequate mechanical accuracy.
PURPOSE: To present a system for the treatment of prostate cancer in a single-fraction regimen using 169 Yb-based rotating shield brachytherapy (RSBT) with a single-catheter robotic delivery system. The proposed system is innovative because it can deliver RSBT through multiple implanted needles independently, in serial, using flexible catheters, with no inter-needle shielding effects and without the need to rotate multiple shielded catheters inside the needles simultaneously, resulting in a simple, mechanically robust, delivery approach. RSBT was compared to conventional 192 Ir-based high-dose-rate brachytherapy (HDR-BT) in a treatment planning study with dose escalation and urethral sparing goals, representing single-fraction brachytherapy monotherapy and brachytherapy as a boost to external beam radiotherapy, respectively. A prototype mechanical delivery system was constructed and quantitatively evaluated as a proof of concept. METHODS: Treatment plans for twenty-six patients with single fraction prescriptions of 20.5 and 15 Gy, were created for dose escalation and urethral sparing, respectively. The RSBT and HDR-BT delivery systems were modeled with one partially shielded 999 GBq (27 Ci) 169 Yb source and one 370 GBq (10 Ci) 192 Ir source, respectively. A prototype angular drive system for helical source delivery was constructed. Mechanical accuracy measurements of source translational position and angular orientation in a simulated treatment delivery setup were obtained using the prototype system. RESULTS: For dose escalation, with equivalent urethra D10% , PTV D90% for RSBT vs HDR-BT increased from 22.6 ± 0.0 Gy (average ± standard deviation) to 29.3 ± 0.9 Gy, or 29.9 % ± 3.0%, with treatment times of 51.4 ± 6.1 min for RSBT and 15.8 ± 2.3 min for 10 Ci 192 Ir-based HDR-BT. For urethra sparing, with equivalent PTV D90 % , urethra D10% for RSBT vs HDR-BT decreased for RSBT vs HDR-BT from 15.6 ± 0.4 Gy to 12.0 ± 0.4 Gy, or 23.1% ± 3.5%, with treatment times of 30.0 ± 3.7 min for RSBT and 12.3 ± 1.8 min for HDR-BT. Differences between measured vs predicted rotating catheter positions (corresponding to source position) were within 0.18 mm ± 0.12 mm longitudinally and 0.07° ± 0.78°. CONCLUSION: 169 Yb-based RSBT can increase PTV D90% or decrease urethral D10% relative to HDR-BT with treatment times of less than 1 h using a single-source robotic delivery system with treatment delivered in a single fraction. The prototype helical delivery system was able to demonstrate adequate mechanical accuracy.
Authors: N Tselis; P Hoskin; D Baltas; V Strnad; N Zamboglou; C Rödel; G Chatzikonstantinou Journal: Clin Oncol (R Coll Radiol) Date: 2017-03-22 Impact factor: 4.126
Authors: Nasiruddin Mohammed; Larry Kestin; Mihai Ghilezan; Daniel Krauss; Frank Vicini; Donald Brabbins; Gary Gustafson; Hong Ye; Alavaro Martinez Journal: Int J Radiat Oncol Biol Phys Date: 2010-12-16 Impact factor: 7.038
Authors: Ryan T Flynn; Quentin E Adams; Karolyn M Hopfensperger; Xiaodong Wu; Weiyu Xu; Yusung Kim Journal: Med Phys Date: 2019-05-27 Impact factor: 4.071
Authors: E Vigneault; G Morton; W R Parulekar; T M Niazi; C W Springer; M Barkati; P Chung; W Koll; A Kamran; M Monreal; K Ding; A Loblaw Journal: Clin Oncol (R Coll Radiol) Date: 2018-06-11 Impact factor: 4.126
Authors: Alfonso Gomez-Iturriaga; Francisco Casquero; Jose Ignacio Pijoan; Pablo Minguez; Jose Maria Espinosa; Ana Irasarri; Andrea Bueso; Jon Cacicedo; David Buchser; Pedro Bilbao Journal: Radiother Oncol Date: 2017-11-15 Impact factor: 6.280